Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).

Weidman, Danielle R; Pole, Jason D; Bouffet, Eric; Taylor, Michael D; Bartels, Ute

Weidman, Danielle R; Pole, Jason D; Bouffet, Eric; Taylor, Michael D; Bartels, Ute.

Affiliation

Weidman DR; Department of Paediatrics, The Hospital for Sick Children, Toronto, Canada.
Pole JD; University of Toronto, Toronto, Canada.
Bouffet E; Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Canada.
Taylor MD; Pediatric Oncology Group of Ontario, Toronto, Canada.
Bartels U; University of Toronto, Toronto, Canada.

Pediatr Blood Cancer ; 62(10): 1754-60, 2015 Oct.

Article in En | MEDLINE | ID: mdl-25929843

Subject(s)

Antineoplastic Agents/administration & dosage; Astrocytoma/drug therapy; Astrocytoma/pathology; TOR Serine-Threonine Kinases/antagonists & inhibitors; Tuberous Sclerosis/complications; Adolescent; Age of Onset; Astrocytoma/etiology; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Infant; Male; Neoplasm Recurrence, Local/drug therapy; Neoplasm Recurrence, Local/pathology; Retrospective Studies

Key words

SEGA; mTOR inhibition; tuberous sclerosis complex

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Astrocytoma / Tuberous Sclerosis / TOR Serine-Threonine Kinases / Antineoplastic Agents Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Language: En Journal: Pediatr Blood Cancer Journal subject: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Year: 2015 Type: Article Affiliation country: Canada

Fulltext

XML

PubMed Links

Search on Google